“Global Ophthalmic Drugs market set to grow to $33bn by 2024” says new Visiongain report

17 June 2019
Pharma

Visiongain has launched a new pharma report Global Ophthalmic Drugs Market Forecast 2019-2029: Dry Eye, Glaucoma Drugs, Retinal Disorders Drugs and Allergic, Inflammatory & Infective Drugs.

The market for ophthalmic drugs is relatively fragmented with a large number of drugs competing for market shares. We note that there are many drugs within the various sectors of the market that have lost exclusivity in the major markets and have therefore been subjected to generic drug competition. Despite generic penetration, the global market for ophthalmic drugs is a growing one with a hive of activities and multiple products in various stages of development.

The lead analyst of the report commented "The market for ophthalmic drugs is a growing one. Although it is currently dominated by a handful of companies, the market still provides opportunities for companies looking to introduce innovative solutions to meet the chronic needs within the market.

Blockbuster drugs are becoming increasingly few within the market as drugs become more targeted. We note that future growth within ophthalmic drugs will likely be driven by innovation from smaller players, possibly in partnership with one of the major companies in the market. The increased demand for drugs and the efforts going into R&D will benefit these smaller players and help to stimulate their growth over the forecast period. With many targeting eye diseases and conditions where significant unmet treatment needs exist, rapid uptake of these products can be expected."

Leading companies featured in the report include Allergan (Actavis), Bayer, Novartis, Pfizer, Regeneron, Roche, Santen, Senju, Valeant and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“The worldwide industry for silicone additives is likely to experience important development”, says Visiongain

It is anticipated that the benefits of silicone additives such as elevated drop, marine strength, and leveling & humidity regulate will boost their use in cosmetics, coatings, and paint applications.

16 October 2019

Read

“Global nephrology and urology devices market is anticipated to surpass USD 39 Bn by 2030”, says Visiongain

Nephrology is a field of medicine that is concerned with studying kidney function, treating kidney issues, and therapy for renal substitute.

16 October 2019

Read

“The global Nasal Drug Delivery Technology market is anticipated to surpass USD 80 Billion by 2030”, says Visiongain

Asia Pacific region is anticipated to experience the highest growth in terms of CAGR over the forecast period owing to the availability of effective treatment methods, high unmet clinical needs, rising disposable income levels, and increasing awareness about these products.

16 October 2019

Read

“The global Myeloproliferative Disorders Drugs market is anticipated to surpass USD 11 Bn by 2030”, says Visiongain

The emergence of a new therapy for myeloproliferative disorders and the accessibility of new drugs is anticipated to drive the market drugs for myeloproliferative disorders.

16 October 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever